HomeBUSINESS
BUSINESS

Novartis Seeks SJIA Indication for Ilaris in Japan
(Oct.26.2017)

Novartis Pharma said on October 25 that it has filed its fully human immunoglobulin G1 (IgG1) monoclonal antibody Ilaris (canakinumab) in Japan for the treatment of systemic juvenile idiopathic arthritis (SJIA) ...
(LOG IN FOR FULL STORY)

News Calendar